CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer



Summary

CARG-2020 is a novel therapeutic strategy designed to treat melanoma and breast cancer by simultaneously targeting three crucial pathways involved in tumor growth and immune evasion. This innovative approach focuses on modulating the immune system to fight cancer by blocking the IL-12 and IL-17 pathways, which are often upregulated in these cancers and contribute to inflammation and tumor progression. Additionally, CARG-2020 targets the PD-L1 pathway, preventing cancer cells from suppressing the immune response. By inhibiting these three key pathways, CARG-2020 aims to enhance anti-tumor immunity and effectively eliminate cancer cells.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!